BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lorigerlimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lorigerlimab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07071961-10812@assetmemo.bio
DTSTAMP:20261121T004524Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Lorigerlimab: Phase 2 readout est. (NCT07071961)
DESCRIPTION:Lorigerlimab\, phase 2.\nStudy: Regorafenib (Reg) and Lorigerli
 mab (Lor)\, RELO Regimen\, in Treatment of High-risk Patients With Colorec
 tal Cancer With Radiographic Occult Molecular Residual Disease After End o
 f Established Definitive Therapy [ReLOAD Trial]\nEstimated primary complet
 ion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lori
 gerlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07071961
URL:https://assetmemo.bio/drug/lorigerlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730347-10812@assetmemo.bio
DTSTAMP:20261121T004524Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Lorigerlimab: Phase 2 readout est. (NCT06730347)
DESCRIPTION:Lorigerlimab\, phase 2.\nStudy: A Study of Lorigerlimab in Part
 icipants With Advanced Solid Tumors\nEstimated primary completion: July 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lorigerlimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06730347
URL:https://assetmemo.bio/drug/lorigerlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05475171-10812@assetmemo.bio
DTSTAMP:20261121T004524Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Lorigerlimab: Phase 2 readout est. (NCT05475171)
DESCRIPTION:Lorigerlimab\, phase 2.\nStudy: Triage of Advanced Cervical Can
 cer Through Immunotherapy Induction (TRACTION)\nEstimated primary completi
 on: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lor
 igerlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05475171
URL:https://assetmemo.bio/drug/lorigerlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07565155-10812@assetmemo.bio
DTSTAMP:20261121T004524Z
DTSTART;VALUE=DATE:20320101
DTEND;VALUE=DATE:20320102
SUMMARY:Lorigerlimab: Phase 2 readout est. (NCT07565155)
DESCRIPTION:Lorigerlimab\, phase 2.\nStudy: Lorigerlimab (MGD019) in Patien
 ts With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency\
 nEstimated primary completion: 1 January 2032. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/lorigerlimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07565155
URL:https://assetmemo.bio/drug/lorigerlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
